News

Virginia Catalyst announces Grant Round 18 awarded teams

August 13, 2025  – The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.4 million in grants to three life and bioscience projects in the Commonwealth of Virginia through a highly-competitive Grant Round 18.

 

“The bioscience ecosystem in Virginia is vibrant, with university researchers, incubator, accelerators, mentors, and VA Bio working together to drive economic development in the Commonwealth.” said Mike Grisham, CEO of Virginia Catalyst. “The Catalyst is proud to provide an avenue of non-diluted funding for these teams to further develop their innovations into commercialization in life sciences.”

 

Through this 18th round of funding, Virginia Catalyst has awarded 72 grants totaling over $38 million, resulting in nearly $56 million in matching funds and over $660 million in follow-on funding and 450 jobs in life sciences.

 

Grant Round 18 Awarded Teams

    

Ceres Nanosciences (Manassas), University of Virginia, and Virginia Tech

  • Awarded: $800,000
  • “Nanotrap® SECURE (Sample Enrichment Concentration Universal RNA/DNA Extraction) Kit”

 

HTIC, Inc. (Charlottesville), University of Virginia, and Virginia Commonwealth University

  • Awarded: $800,000
  • “Developing a first-in-class humanized monoclonal antibody for immune modulation in human diseases”

  

RIVANNA Medical, Inc. (Charlottesville), University of Virginia, and Virginia Commonwealth University

  • Awarded: $800,000
  • “Transforming epidural placement with precision-guided technology to enhance safety and patient satisfaction”

 

 

Read more here.

 

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin